Published in Curr Top Microbiol Immunol on January 01, 1995
Sociometric risk networks and risk for HIV infection. Am J Public Health (1997) 3.29
The network approach and interventions to prevent HIV among injection drug users. Public Health Rep (1998) 1.96
Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol (1996) 1.94
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology (2006) 1.66
Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56
Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol (1998) 1.52
V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol (1999) 1.49
Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism. J Virol (1996) 1.47
Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology (2007) 1.43
Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. J Virol (2000) 1.12
Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long-range PCR. J Virol (1997) 1.07
Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PLoS One (2010) 0.96
Productive infection of human peripheral blood mononuclear cells by feline immunodeficiency virus: implications for vector development. J Virol (1999) 0.93
Neurovirulence in feline immunodeficiency virus-infected neonatal cats is viral strain specific and dependent on systemic immune suppression. J Virol (1998) 0.90
Efficient transmission and persistence of low-frequency SIVmac251 variants in CD8-depleted rhesus macaques with different neuropathology. J Gen Virol (2012) 0.89
Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region on the viral genome. J Virol (1996) 0.89
Envelope gene-mediated neurovirulence in feline immunodeficiency virus infection: induction of matrix metalloproteinases and neuronal injury. J Virol (2002) 0.86
Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. Future Virol (2010) 0.86
From human immunodeficiency virus (HIV) infection of the brain to dementia. Genitourin Med (1997) 0.82
Neurovirulence of polytropic murine retrovirus is influenced by two separate regions on opposite sides of the envelope protein receptor binding domain. J Virol (2008) 0.82
Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. BMC Neurol (2010) 0.79
Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence. FASEB J (2013) 0.79
Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5. Virology (2015) 0.77
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. Nature (1970) 5.90
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (1993) 4.81
Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology (2011) 4.63
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) (1968) 4.40
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Mammalian cell fusion: induction of premature chromosome condensation in interphase nuclei. Nature (1970) 4.21
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
Molecular basis of Sindbis virus neurovirulence in mice. J Virol (1988) 3.90
Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol (1995) 3.78
Antibody-mediated clearance of alphavirus infection from neurons. Science (1991) 3.70
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998. Neurology (2001) 3.55
Mechanism of suppression of cell-mediated immunity by measles virus. Science (1996) 3.55
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 3.17
EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol (2005) 3.17
Antigenic shift of visna virus in persistently infected sheep. Science (1977) 3.17
Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology (2007) 3.14
Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med (1972) 3.09
Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89
Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A (1998) 2.89
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
Binding of Sindbis virus to cell surface heparan sulfate. J Virol (1998) 2.82
Selection of a fixative for identifying T cell subsets, B cells, and macrophages in paraffin-embedded mouse spleen. J Immunol Methods (1983) 2.82
Characterization of Shigella dysenteriae 1 (Shiga) toxin purified by anti-Shiga toxin affinity chromatography. Infect Immun (1980) 2.82
Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell (1986) 2.69
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65
Alphavirus-induced apoptosis in mouse brains correlates with neurovirulence. J Virol (1996) 2.65
Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet (1991) 2.60
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Age-dependent resistance to viral encephalitis: studies of infections due to Sindbis virus in mice. J Infect Dis (1972) 2.56
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology (1995) 2.55
Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54
Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol (1992) 2.52
Activation of caprine arthritis-encephalitis virus expression during maturation of monocytes to macrophages. Infect Immun (1983) 2.52
Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology (1999) 2.52
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology (1999) 2.49
Pathogenesis of viral infections of the nervous system. N Engl J Med (1968) 2.48
Clinical-neuropathologic correlation in HIV-associated dementia. Neurology (1993) 2.47
Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology (1985) 2.44
Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci U S A (1998) 2.42
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/. Nature (1994) 2.35
Role of the immune response in recovery from Sindbis virus encephalitis in mice. J Immunol (1977) 2.32
Bc1-2 protects mice against fatal alphavirus encephalitis. Proc Natl Acad Sci U S A (1996) 2.31
Scrapie infectivity found in resistant species. Nature (1998) 2.28
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol (1996) 2.22
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Purification and biological characterization of shiga toxin from Shigella dysenteriae 1. Infect Immun (1982) 2.21
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
Neuropsychological performance in HIV-1-infected homosexual men: The Multicenter AIDS Cohort Study (MACS) Neurology (1990) 2.17
Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology (2002) 2.17
Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology (1997) 2.15
Infection of monocytes during measles. J Infect Dis (1993) 2.14
Complementation analysis on virus-fused Chinese hamster cells with nutritional markers. Science (1969) 2.12
Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol (1993) 2.09
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev (2000) 2.06
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology (2006) 2.06
Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol (1998) 2.05
Basis of neurovirulence in Sindbis virus encephalomyelitis of mice. Lab Invest (1988) 2.05
Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol (1987) 2.05
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
Apoptosis as a cause of death in measles virus-infected cells. J Virol (1995) 1.97
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Aleutian disease of mink: the antibody response of sapphire and pastel mink to Aleutian disease virus. J Immunol (1975) 1.95
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Interferon-gamma-mediated site-specific clearance of alphavirus from CNS neurons. Science (2001) 1.95
Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology (1995) 1.95
Viral determinants of age-dependent virulence of Sindbis virus for mice. J Virol (1993) 1.95